325 related articles for article (PubMed ID: 33398769)
1. Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment.
Raven LM; Guttman-Jones M; Muir CA
Endocrine; 2021 May; 72(2):524-528. PubMed ID: 33398769
[TBL] [Abstract][Full Text] [Related]
2. New Insights Into Extended Steroid Hormone Profiles in Transwomen in a Multi-Center Setting in Germany.
Schneider F; Wistuba J; Holterhus PM; Kulle A; Schlatt S; Kliesch S; Neuhaus N; Zitzmann M
J Sex Med; 2021 Oct; 18(10):1807-1817. PubMed ID: 34600646
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy.
Hashemi L; Zhang Q; Getahun D; Jasuja GK; McCracken C; Pisegna J; Roblin D; Silverberg MJ; Tangpricha V; Vupputuri S; Goodman M
J Sex Med; 2021 Sep; 18(9):1662-1675. PubMed ID: 34366264
[TBL] [Abstract][Full Text] [Related]
4. Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study.
Suppakitjanusant P; Ji Y; Stevenson MO; Chantrapanichkul P; Sineath RC; Goodman M; Alvarez JA; Tangpricha V
J Clin Transl Endocrinol; 2020 Sep; 21():100230. PubMed ID: 32685379
[TBL] [Abstract][Full Text] [Related]
5. Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations.
Jasuja GK; Wolfe HL; Reisman JI; Vimalananda VG; Rao SR; Blosnich JR; Livingston NA; Shipherd JC
Front Endocrinol (Lausanne); 2024; 15():1086158. PubMed ID: 38800485
[TBL] [Abstract][Full Text] [Related]
6. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI).
Cocchetti C; Castellini G; Iacuaniello D; Romani A; Maggi M; Vignozzi L; Schreiner T; den Heijer M; T'Sjoen G; Fisher AD
J Sex Med; 2021 Apr; 18(4):821-829. PubMed ID: 33745831
[TBL] [Abstract][Full Text] [Related]
7. Effects of gender-affirming hormone therapy on body fat: a retrospective case‒control study in Chinese transwomen.
Pei Q; Song Y; Huang Z; Yu H; Xu H; Ye X; Gao L; Gong J; Tian X
Lipids Health Dis; 2024 May; 23(1):146. PubMed ID: 38760846
[TBL] [Abstract][Full Text] [Related]
8. Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks.
Sudhakar D; Huang Z; Zietkowski M; Powell N; Fisher AR
Neurourol Urodyn; 2023 Jun; 42(5):903-920. PubMed ID: 36403287
[TBL] [Abstract][Full Text] [Related]
9. Which U.S. States' Medicaid Programs Provide Coverage for Gender-Affirming Hormone Therapy and Gender-Affirming Genital Surgery for Transgender Patients?: A State-by-State Review, and a Study Detailing the Patient Experience to Confirm Coverage of Services.
Zaliznyak M; Jung EE; Bresee C; Garcia MM
J Sex Med; 2021 Feb; 18(2):410-422. PubMed ID: 33422448
[TBL] [Abstract][Full Text] [Related]
10. Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen.
Scheres LJJ; Selier NLD; Nota NM; van Diemen JJK; Cannegieter SC; den Heijer M
J Thromb Haemost; 2021 Apr; 19(4):1029-1037. PubMed ID: 33527671
[TBL] [Abstract][Full Text] [Related]
11. Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study.
Salakphet T; Mattawanon N; Manojai N; Muangmool T; Tangpricha V
J Sex Med; 2022 May; 19(5):864-871. PubMed ID: 35379590
[TBL] [Abstract][Full Text] [Related]
12. Gender affirming hormonal treatment in Danish transgender persons: A nationwide register-based study.
Glintborg D; Rubin KH; Kristensen SB; Lidegaard Ø; T'Sjoen G; Hilden M; Andersen MS
Andrology; 2022 Jul; 10(5):885-893. PubMed ID: 35366390
[TBL] [Abstract][Full Text] [Related]
13. Gender-affirming hormone therapy induces specific DNA methylation changes in blood.
Shepherd R; Bretherton I; Pang K; Mansell T; Czajko A; Kim B; Vlahos A; Zajac JD; Saffery R; Cheung A; Novakovic B
Clin Epigenetics; 2022 Feb; 14(1):24. PubMed ID: 35177097
[TBL] [Abstract][Full Text] [Related]
14. [Hyperprolactinemia unrelated to prolactinoma].
Krysiak R; Okopień B
Wiad Lek; 2014; 67(2 Pt 1):101-11. PubMed ID: 25764785
[TBL] [Abstract][Full Text] [Related]
15. Laboratory Changes During Gender-Affirming Hormone Therapy in Transgender Adolescents.
Millington K; Lee JY; Olson-Kennedy J; Garofalo R; Rosenthal SM; Chan YM
Pediatrics; 2024 May; 153(5):. PubMed ID: 38567424
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of and factors associated with the use of gender-affirming hormonal therapy outside the reference regimen among transgender people in a community-led clinic in Metro Manila, Philippines: a retrospective cross-sectional study.
Eustaquio PC; Dela Cruz JDM; Araña Y; Rosos B; Rosadiño JDT; Pagtakhan RG; Regencia ZJG; Baja ES
BMJ Open; 2023 Sep; 13(9):e072252. PubMed ID: 37669846
[TBL] [Abstract][Full Text] [Related]
17. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review.
McFarlane T; Zajac JD; Cheung AS
Clin Endocrinol (Oxf); 2018 Dec; 89(6):700-711. PubMed ID: 30107028
[TBL] [Abstract][Full Text] [Related]
18. A single- center experience of prolactin-producing pituitary adenomas without hyperprolactinemia: Its incidence and clinical management.
Ogawa Y; Tominaga T
Clin Neurol Neurosurg; 2020 Nov; 198():106123. PubMed ID: 32818756
[TBL] [Abstract][Full Text] [Related]
19. Association of Gender-Affirming Hormone Therapy With Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth.
Green AE; DeChants JP; Price MN; Davis CK
J Adolesc Health; 2022 Apr; 70(4):643-649. PubMed ID: 34920935
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
